SI-BONE, Inc.

NasdaqGM:SIBN 株式レポート

時価総額:US$651.0m

SI-BONE 将来の成長

Future 基準チェック /16

SI-BONEは、12.6%と14%でそれぞれ年率12.6%で利益と収益が成長すると予測される一方、EPSはgrowで14.1%年率。

主要情報

12.6%

収益成長率

14.06%

EPS成長率

Medical Equipment 収益成長16.1%
収益成長率14.0%
将来の株主資本利益率n/a
アナリストカバレッジ

Good

最終更新日12 May 2026

今後の成長に関する最新情報

分析記事 May 14

Analysts Have Been Trimming Their SI-BONE, Inc. (NASDAQ:SIBN) Price Target After Its Latest Report

SI-BONE, Inc. ( NASDAQ:SIBN ) just released its latest first-quarter results and things are looking bullish. Results...
分析記事 Nov 13

Earnings Update: SI-BONE, Inc. (NASDAQ:SIBN) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts

SI-BONE, Inc. ( NASDAQ:SIBN ) just released its third-quarter report and things are looking bullish. Revenues and...

Recent updates

ナラティブの更新 May 22

SIBN: 2026 Guidance And Trauma Partnership Will Drive Further Upside

Analysts have trimmed their price target on SI-BONE from $22.00 to $18.00 as updated assumptions now reflect slightly lower revenue growth, a modestly reduced profit margin outlook, and a lower future P/E multiple, partly offset by a small adjustment to the discount rate. What's in the News SI-BONE issued earnings guidance for 2026, with worldwide revenue expected in a range of $228.5 million to $232.5 million, implying year-over-year growth of about 14% to 16% (Key Developments).
分析記事 May 14

Analysts Have Been Trimming Their SI-BONE, Inc. (NASDAQ:SIBN) Price Target After Its Latest Report

SI-BONE, Inc. ( NASDAQ:SIBN ) just released its latest first-quarter results and things are looking bullish. Results...
ナラティブの更新 Apr 12

SIBN: 2026 Guidance And Trauma Partnership Will Support Further Upside

Analysts have kept SI-BONE's price target steady at $22.00, citing only modest tweaks to inputs such as the discount rate, revenue growth, profit margin, and forward P/E assumptions, rather than any major change in their overall view. What's in the News Smith+Nephew signed a distribution agreement with SI-BONE focused on the iFuse TORQ portfolio for percutaneous pelvic fracture fixation procedures and sacroiliac joint fusion, expanding access to these products through Smith+Nephew's trauma portfolio and SI-BONE's existing sales channel (Key Developments).
ナラティブの更新 Mar 29

SIBN: 2026 Outlook And Pelvic Fixation Partnership Will Support Upside

Analysts now hold their price target for SI-BONE steady at $22.00. This reflects only small tweaks to assumptions around discount rate, revenue growth, profit margin, and future P/E that do not materially shift their overall valuation view.
ナラティブの更新 Mar 11

SIBN: 2026 Revenue Outlook And Pelvic Fixation Deal Will Support Upside

Analysts have held their SI-BONE price target steady at $22.00, with only modest tweaks to assumptions on discount rate, revenue growth, profit margin, and future P/E, reflecting fine tuning rather than a shift in their overall view. What's in the News Smith+Nephew signed a distribution agreement with SI-BONE focused on the iFuse TORQ portfolio for percutaneous pelvic fracture fixation procedures and sacroiliac (SI) joint fusion, broadening access to these products through Smith+Nephew's trauma channel alongside SI-BONE's existing salesforce (Key Developments).
ナラティブの更新 Feb 25

SIBN: 2026 Revenue Outlook And New Distribution Deal Will Support Upside

Analysts have trimmed their price target for SI-BONE from $23.00 to $22.00, reflecting updated assumptions that include slightly lower revenue growth expectations, a modestly higher profit margin outlook, and a revised forward P/E multiple. What's in the News SI-BONE issued earnings guidance for 2026, projecting worldwide revenue in a range of $228.5 million to $232.5 million, with implied year over year growth guidance of about 14% to 16% (company guidance).
ナラティブの更新 Jan 19

SIBN: Higher 2025 Revenue Guidance Will Support Future Upside Potential

Analysts have maintained their fair value estimate for SI-BONE at $23.00. They made small adjustments to assumptions such as discount rate, revenue growth, profit margin, and future P/E, which together support this reaffirmed target.
ナラティブの更新 Jan 04

SIBN: Raised 2025 Revenue Guidance Will Drive Stronger Profitability And Share Price Upside

Analysts have modestly lowered their price target on SI-BONE to 23.00 dollars per share, reflecting a slightly higher discount rate and a marginally lower expected future price to earnings multiple, even as they factor in stronger long term revenue growth prospects. What's in the News SI-BONE raised its 2025 revenue guidance to a range of 198 million to 200 million dollars, up from 195 million to 198 million dollars previously.
ナラティブの更新 Dec 19

SIBN: Raised Revenue Guidance Will Support Stronger Profitability And Share Price Upside

Analysts have raised their price target on SI-BONE from 20 dollars to 23 dollars, citing slightly stronger expectations for revenue growth, profitability, and long term valuation multiples. What's in the News Company raised 2025 revenue guidance to a range of 198 million dollars to 200 million dollars, up from a prior range of 195 million dollars to 198 million dollars, signaling increased confidence in demand trends (company guidance filing) The updated outlook implies faster top line growth than previously anticipated and supports analysts' upward revisions to price targets and long term valuation assumptions (company guidance filing) The narrowing of the revenue guidance range suggests greater visibility into procedure volumes and commercial execution for the remainder of the year (company guidance filing) Valuation Changes The fair value estimate has risen slightly from 20 dollars to 23 dollars per share, reflecting modestly stronger growth and profitability assumptions.
分析記事 Nov 13

Earnings Update: SI-BONE, Inc. (NASDAQ:SIBN) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts

SI-BONE, Inc. ( NASDAQ:SIBN ) just released its third-quarter report and things are looking bullish. Revenues and...
分析記事 Nov 12

Getting In Cheap On SI-BONE, Inc. (NASDAQ:SIBN) Might Be Difficult

SI-BONE, Inc.'s ( NASDAQ:SIBN ) price-to-sales (or "P/S") ratio of 4.1x may not look like an appealing investment...
分析記事 Jun 26

Is SI-BONE (NASDAQ:SIBN) Using Debt In A Risky Way?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
分析記事 May 09

Earnings Update: SI-BONE, Inc. (NASDAQ:SIBN) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts

SI-BONE, Inc. ( NASDAQ:SIBN ) investors will be delighted, with the company turning in some strong numbers with its...
分析記事 May 08

Revenues Tell The Story For SI-BONE, Inc. (NASDAQ:SIBN) As Its Stock Soars 30%

SI-BONE, Inc. ( NASDAQ:SIBN ) shareholders would be excited to see that the share price has had a great month, posting...
分析記事 Mar 27

SI-BONE (NASDAQ:SIBN) Has Debt But No Earnings; Should You Worry?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
User avatar
新しいナラティブ Mar 26

TORQ And TNT Will Expand Market Reach In 2025

Strong product launches and a robust innovation pipeline suggest promising future revenue growth and strengthened market positioning.
分析記事 Jan 19

SI-BONE, Inc. (NASDAQ:SIBN) Looks Just Right With A 26% Price Jump

SI-BONE, Inc. ( NASDAQ:SIBN ) shareholders have had their patience rewarded with a 26% share price jump in the last...
分析記事 Nov 04

Market Cool On SI-BONE, Inc.'s (NASDAQ:SIBN) Revenues

There wouldn't be many who think SI-BONE, Inc.'s ( NASDAQ:SIBN ) price-to-sales (or "P/S") ratio of 3.7x is worth a...
分析記事 Sep 25

Is SI-BONE (NASDAQ:SIBN) Using Too Much Debt?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
分析記事 Apr 01

SI-BONE, Inc.'s (NASDAQ:SIBN) P/S Is On The Mark

SI-BONE, Inc.'s ( NASDAQ:SIBN ) price-to-sales (or "P/S") ratio of 4.8x might make it look like a sell right now...
分析記事 Feb 29

Analyst Estimates: Here's What Brokers Think Of SI-BONE, Inc. (NASDAQ:SIBN) After Its Full-Year Report

It's been a sad week for SI-BONE, Inc. ( NASDAQ:SIBN ), who've watched their investment drop 14% to US$17.35 in the...
分析記事 Feb 28

Is SI-BONE (NASDAQ:SIBN) Using Debt In A Risky Way?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
分析記事 Nov 12

Is SI-BONE (NASDAQ:SIBN) Using Too Much Debt?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
分析記事 Aug 09

Is SI-BONE (NASDAQ:SIBN) Using Too Much Debt?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
分析記事 Apr 20

Is SI-BONE (NASDAQ:SIBN) A Risky Investment?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
分析記事 Jan 01

Is SI-BONE (NASDAQ:SIBN) Using Debt In A Risky Way?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...

業績と収益の成長予測

NasdaqGM:SIBN - アナリストの将来予測と過去の財務データ ( )USD Millions
日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数
12/31/2028304-11N/A303
12/31/2027267-1719218
12/31/2026232-20-6-28
3/31/2026206-17-62N/A
12/31/2025201-19-9-1N/A
9/30/2025194-22-11-1N/A
6/30/2025185-24-13-3N/A
3/31/2025177-27-20-10N/A
12/31/2024167-31-23-12N/A
9/30/2024157-37-25-16N/A
6/30/2024151-41-26-18N/A
3/31/2024144-43-23-16N/A
12/31/2023139-43-27-19N/A
9/30/2023132-44-32-23N/A
6/30/2023124-48-38-28N/A
3/31/2023117-55-49-39N/A
12/31/2022106-61-51-42N/A
9/30/2022100-65-57-48N/A
6/30/202296-66-57-50N/A
3/31/202292-62-50-44N/A
12/31/202190-57-46-40N/A
9/30/202187-51-40-35N/A
6/30/202185-45-36-31N/A
3/31/202177-43-34-31N/A
12/31/202073-44-33-31N/A
9/30/202071-44-34-32N/A
6/30/202067-46-36-33N/A
3/31/202069-42-37-34N/A
12/31/201967-38N/A-32N/A
9/30/201963-35N/A-29N/A
6/30/201960-28N/A-24N/A
3/31/201958-23N/A-17N/A
12/31/201855-17N/A-15N/A
9/30/201854-17N/A-12N/A
6/30/201852-18N/A-14N/A
3/31/201849-21N/A-17N/A
12/31/201748-23N/A-18N/A
3/31/201744-21N/A-16N/A
12/31/201642-21N/A-17N/A
3/31/201640-27N/A-25N/A
12/31/201541-28N/A-27N/A
9/30/201542-32N/A-27N/A

アナリストによる今後の成長予測

収入対貯蓄率: SIBN今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: SIBN今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: SIBN今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: SIBNの収益 ( 14% ) US市場 ( 11.7% ) よりも速いペースで成長すると予測されています。

高い収益成長: SIBNの収益 ( 14% ) 20%よりも低い成長が予測されています。


一株当たり利益成長率予想


将来の株主資本利益率

将来のROE: SIBNの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です


成長企業の発掘

企業分析と財務データの現状

データ最終更新日(UTC時間)
企業分析2026/05/26 04:54
終値2026/05/26 00:00
収益2026/03/31
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM(Trailing Twelve Month)またはLTM(Last Twelve Month)データとして知られています。詳細はこちら

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

SI-BONE, Inc. 8 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。16

アナリスト機関
Travis SteedBofA Global Research
Caitlin CroninCanaccord Genuity
Ross OsbornCantor Fitzgerald & Co.